PGR and cancer: Recent recommendations from the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) for ER and PR test reporting include the introduction of a new category of “ER Low Positive” in light of limited data on the benefit of endocrine therapy for cancers with 1% to 10% of ER+ cells [35].